Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Sci Rep 2017 08 1;7(1):7066. Epub 2017 Aug 1.

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Accumulating evidence supports a role of the PI3K-AKT pathway in the regulation of cell motility, invasion and metastasis. AKT activation is known to promote metastasis, however under certain circumstances, it also shows an inhibitory activity on metastatic processes, and the cause of such conflicting results is largely unclear. Here we found that AKT1 is an important regulator of metastasis and down-regulation of its activity is associated with increased metastatic potential of A549 cells. Inhibition of AKT1 enhanced migration and invasion in KRAS- or EGFR-mutant non-small cell lung cancer (NSCLC) cells. The allosteric AKT inhibitor MK-2206 promoted metastasis of KRAS-mutated A549 cells in vivo. We next identified that the phosphorylation of Myristoylated alanine-rich C-kinase substrate (MARCKS) and LAMC2 protein level were increased with AKT1 inhibition, and MARCKS or LAMC2 knockdown abrogated migration and invasion induced by AKT1 inhibition. This study unravels an anti-metastatic role of AKT1 in the NSCLC cells with KRAS or EGFR mutations, and establishes an AKT1-MARCKS-LAMC2 feedback loop in this regulation.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-06128-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539338PMC
August 2017
74 Reads

Publication Analysis

Top Keywords

lung cancer
8
cell lung
8
non-small cell
8
egfr mutations
8
migration invasion
8
akt1 inhibition
8
marcks lamc2
8
nsclc cells
8
invasion metastasis
8
a549 cells
8
inhibition akt1
8
akt1
5
metastasis
5
cells
5
akt inhibitor
4
identified phosphorylation
4
allosteric akt
4
cells allosteric
4
akt1 signaling
4
inhibitor mk-2206
4

References

(Supplied by CrossRef)

RL Siegel et al.
CA: a cancer journal for clinicians 2015

RS Herbst et al.
The New England journal of medicine 2008

NM-aC Group et al.
Lancet 2010

C Greenman et al.
Nature 2007

W Pao et al.
The Lancet. Oncology 2011

JA Engelman et al.
Nature reviews. Cancer 2009

ML Sos et al.
Cancer research 2009

JA Engelman et al.
The Journal of clinical investigation 2006

ZZ Yang et al.
The Journal of biological chemistry 2003

M Yoeli-Lerner et al.
Molecular cell 2005

GL Zhou et al.
The Journal of biological chemistry 2006

Similar Publications